Skip to content
ChickenStockChickenStock
Research041960
Komipharm International logo

Komipharm International (041960) stock

KOSDAQ · Pharmaceuticals

KRW 8,130-3.33%(-280)

As of Nov 16, 3:06 PM KST

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-89.93x

Net loss — not comparable

P/B

8.46x

P/S

11.52x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Aug 13, 2026KRW 16.7 billionKRW 1.6 billionKRW 500 million+22.1%
Q1 2026Consolidated · Filed May 14, 2026KRW 11.9 billionKRW 300 millionKRW 700 million-17.2%
Q4 2025Consolidated · Filed Mar 18, 2026KRW 11.9 billion-KRW 200 million-KRW 4.3 billion—
Q3 2025Consolidated · Filed Nov 14, 2025KRW 12.5 billionKRW 100 million-KRW 300 million+13.6%
Q2 2025Consolidated · Filed Aug 13, 2025KRW 13.7 billionKRW 1.6 billion-KRW 3.3 billion-28.6%
Q1 2025Consolidated · Filed May 14, 2025KRW 14.4 billionKRW 500 million-KRW 100 million+11.7%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed Mar 18, 2026KRW 52.5 billionKRW 2 billion-KRW 8 billion—
FY2024Consolidated · Filed Mar 18, 2025KRW 58.8 billionKRW 6.2 billionKRW 14.7 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
5.47%
Of trading value on Nov 13, 2026
Short-sale value
KRW 60 million
Previous 20-day average 7.52%
Net short position
866,489 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
3,095,385 shares
As of Nov 13, 2026 · 4.15% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 20265.47%KRW 60 million
Nov 12, 20260.39%KRW 0
Nov 11, 20262.58%KRW 40 million
Nov 10, 20260.57%KRW 10 million
Nov 9, 20264.24%KRW 50 million
Nov 6, 20262.27%KRW 40 million
Nov 5, 20269.62%KRW 110 million
Nov 4, 20265.61%KRW 60 million
Nov 3, 202612.38%KRW 110 million
Nov 2, 20269.03%KRW 140 million

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

Komipharm International (041960) stock information

KOSDAQ

Komipharm International (041960) is listed on KOSDAQ. Its market capitalization is about KRW 606.6 billion. On trailing-twelve-month earnings the P/E ratio is -89.93, and the P/B ratio is 8.46. Return on equity is -9.4%. These figures are computed in-house from official filings and are reference information only.

Komipharm International — frequently asked questions

What is the P/E ratio of Komipharm International (041960)?
On a trailing-twelve-month basis, 041960 trades at a P/E ratio of -89.93. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Komipharm International?
041960 has a market capitalization of about KRW 606.6 billion. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.